Clinical Trials Logo

Filter by:
NCT ID: NCT04586010 Active, not recruiting - Clinical trials for Relapsing Multiple Sclerosis

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

FENhance
Start date: March 17, 2021
Phase: Phase 3
Study type: Interventional

A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized 1:1 to either fenebrutinib or teriflunomide. Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study.

NCT ID: NCT04584788 Completed - Oxygen Deficiency Clinical Trials

Validation of the O3 Regional Somatic Tissue Oxygenation Monitor

Start date: November 30, 2020
Phase: N/A
Study type: Interventional

Testing the absolute accuracy of the Masimo O3 regional oximeter in reading somatic tissue oxygenation in healthy volunteers under controlled hypoxia.

NCT ID: NCT04583917 Recruiting - Clinical trials for Duchenne Muscular Dystrophy

Brain Involvement in Dystrophinopathies Part 1

Start date: March 30, 2021
Phase:
Study type: Observational

The objective of this study is to collect data from a large cohort of individuals with DMD and BMD focusing on the neurobehavioural aspects of these conditions and their correlation to the location of the DMD gene mutation.

NCT ID: NCT04582786 Recruiting - Pain, Acute Clinical Trials

Dose Finding Study of STR-324

Start date: December 1, 2020
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the analgesic effect and the safety of 4 doses of STR-324 administered as an infusion, with or without initial bolus, to patients suffering from post-operative pain. The sensitivity of the pain model used in the trial will be evaluated with a standard group treated with morphine under the usual care conditions.

NCT ID: NCT04582305 Active, not recruiting - Keloid Clinical Trials

Bleomycin Jet Injections in Keloids

Start date: March 18, 2022
Phase: Phase 4
Study type: Interventional

This is a single center, double-blind (patient and investigator), randomized, placebo-controlled study with a split-lesion design, in which selected keloids will receive three consecutive treatments of a) bleomycin and b) placebo (saline (NaCl 0,9%)), administered with an electronic pneumatic jet injector.

NCT ID: NCT04581512 Recruiting - Clinical trials for Acute Myeloid Leukemia

Study to Evaluate the Safety and Tolerability of EP0042

Start date: November 2, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).

NCT ID: NCT04580914 Completed - Clinical trials for Paroxysmal Atrial Fibrillation

Clinical Evaluation of the StablePoint Catheter and Force Sensing System for Paroxysmal Atrial Fibrillation

NEwTON AF
Start date: April 12, 2021
Phase: N/A
Study type: Interventional

The NEwTON AF study is a multi-center, global, prospective, single arm study to establish the safety and effectiveness of the IntellaNav StablePoint Catheter and Force-Sensing System in subjects with symptomatic, drug refractory, recurrent paroxysmal atrial fibrillation.

NCT ID: NCT04579666 Terminated - Clinical trials for Amyotrophic Lateral Sclerosis

MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

Start date: September 30, 2020
Phase: Phase 2
Study type: Interventional

This is a 24-month, Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS)

NCT ID: NCT04579380 Active, not recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Start date: January 11, 2021
Phase: Phase 2
Study type: Interventional

This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get a drug called fulvestrant. The trial will also look at what side effects happen. A side effect is anything a drug does besides treating cancer.

NCT ID: NCT04578834 Active, not recruiting - IgA Nephropathy Clinical Trials

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

APPLAUSE-IgAN
Start date: January 25, 2021
Phase: Phase 3
Study type: Interventional

The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.